ad image

Depression

1 / 1
Sage Therapeutics

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Sage Therapeutics

PR-M06-21-023Jun 18, 2021
VistaGen Therapeutics
Clinical Results

VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder

VistaGen Therapeutics

PR-M11-19-NI-019Nov 19, 2019
Looking Beyond Current Treatments for CNS Diseases and Disorders
Drug Development

Looking Beyond Current Treatments for CNS Diseases and Disorders

Shawn Singh

VistaGen Therapeutics

PAP-Q3-19-CL-036Oct 28, 2019
Trump Urges VA to Use Spravato
Depression

Trump Urges VA to Use Spravato

Nice Insight

PAO-M00-19-NI-007Sep 04, 2019
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
Phase III

Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression

Nice Insight

PR-M07-19-NI-023Jul 10, 2019
NeuroRx
Drug Development

NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

NeuroRx

PR-M06-19-NI-004Jun 07, 2019
Failed Depression Drug Could be Opioid Addiction Treatment
Opioid Treatment

Failed Depression Drug Could be Opioid Addiction Treatment

Emilie Branch

Pharma's Almanac

PAO-M04-19-NI-012Apr 10, 2019
Using Genetic Data to Fight Depression
Genetic Testing

Using Genetic Data to Fight Depression

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M04-19-NI-001Apr 02, 2019
U.S. Food & Drug Administration
FDA Approval

FDA Approves New Nasal Spray Medication for Treatment-resistant Depression; Available Only at a Certified Doctor's Office or Clinic

U.S. Food & Drug Administration

PR-M03-19-NI-027Mar 11, 2019
Janssen Pharmaceutical Companies
FDA

FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

Janssen Pharmaceutical Companies

PR-M02-19-NI-030Feb 14, 2019
Depression Drug Shows Early Positive Results
Clinical Trials

Depression Drug Shows Early Positive Results

Emilie Branch

Pharma's Almanac

PAO-M01-19-NI-014Jan 25, 2019
Janssen Pharmaceutical Companies
Depression

New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans

Janssen Pharmaceutical Companies

PR-M10-18-NI-104Oct 30, 2018
The Neuro-Laser Foundation
Innovation

Shining a Light on Depression - How Infrared Light Can Treat Depression

The Neuro-Laser Foundation

PR-M10-18-NI-030Oct 09, 2018
Janssen Pharmaceutical Companies
Data Presentation

Janssen to Present Data in Treatment-Resistant Mental Ilnesses

Janssen Pharmaceutical Companies

PR-M05-18-NI-029May 08, 2018
1 / 1